Ann: Investor Presentation - Spark Plus Healthcare Day, page-8

The continuing lack of announced detail concerning the burns trial is obviously both puzzling and irritating to we financially committed observers and is the subject of continuing posts on these threads.

The trial is obviously still continuing and it may be that suitable patients are not often presenting for the trial but I would wonder also if there might be some IP implications that are the origin of the apparent tardiness.

If there have been changes in the method of administration or in the formula, such as to overcome the sting phenomenon originally reported, or to increase efficacy in this type of use, it might be that the potential problem of prior publication compromising the validity of anticipated patent submissions are the cause of the lack of information.

Just another possibility to conjure.

poorinvestor